Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Ginkgo Bioworks Holdings Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.59 (market cap $4.59B), while Ginkgo Bioworks Holdings Inc trades at $11.78 (market cap $763.64M). The key difference: Definium Therapeutics Inc. Common Shares is far larger — about 6× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is more actively traded (3,204,177 versus 2,103,937). Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Ginkgo Bioworks Holdings Inc for 7 Days on average.
| DFTX | DNA | |
|---|---|---|
Market Cap | $4.59B | $763.64M |
Volume | 2,103,937 | 3,204,177 |
Sector | Health | Health |
52-Week High | $48.45 | $15.83 |
52-Week Low | $10.68 | $5.48 |
Typical Hold Time | 0 Days | 7 Days |
Enterprise Value | $3.55B | $865.59M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
